R. Nair

发表

Signaling networks associated with BCR-ABL-dependent transformation.

L. Hazlehurst, N. Bewry, R. Nair, 2009, Cancer control : journal of the Moffitt Cancer Center.

The MitoNEET Ligand NL-1 Mediates Antileukemic Activity in Drug-Resistant B-Cell Acute Lymphoblastic Leukemia

W. Geldenhuys, R. Nair, D. Piktel, 2019, The Journal of Pharmacology and Experimental Therapeutics.

Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance

D. Boulware, L. Hazlehurst, N. Bewry, 2008, Molecular Cancer Therapeutics.

The bone marrow microenvironment as a sanctuary for minimal residual disease in CML.

L. Hazlehurst, R. Nair, Joel H. Tolentino, 2010, Biochemical pharmacology.

Crystal structure of the mitochondrial protein mitoNEET bound to a benze-sulfonide ligand

W. Geldenhuys, L. Hazlehurst, R. Nair, 2019, Communications Chemistry.

Title: Acquisition of resistance towards HYD1 correlates with a reduction in cleaved alpha 4 integrin expression and a compromised CAM-DR phenotype Cleaved alpha 4 integrin expression correlates with resistance to HYD1

A. Cress, L. Hazlehurst, R. Nair, 2011 .

Lung cancer cells survive epidermal growth factor receptor tyrosine kinase inhibitor exposure through upregulation of cholesterol synthesis

R. Nair, S. Mohapatra, Waise Quarni, 2019, FASEB bioAdvances.

Actinomycin D Down-regulates SOX2 Expression and Induces Death in Breast Cancer Stem Cells.

R. Nair, S. Mohapatra, S. Mohapatra, 2017, Anticancer research.

Actinomycin D and Telmisartan Combination Targets Lung Cancer Stem Cells Through the Wnt/Beta Catenin Pathway

R. Nair, S. Mohapatra, S. Mohapatra, 2019, Scientific Reports.

Expression cloning of novel regulators of 92 kDa type IV collagenase expression.

R. Nair, D. Boyd, 2005, Biochemical Society transactions.

Potentiation of Nilotinib-mediated cell death in the context of the bone marrow microenvironment requires a promiscuous JAK inhibitor in CML.

L. Hazlehurst, R. Nair, J. Pinilla-Ibarz, 2012, Leukemia research.

Combination of cabazitaxel and plicamycin induces cell death in drug resistant B-cell acute lymphoblastic leukemia.

W. Geldenhuys, R. Nair, D. Piktel, 2018, Leukemia research.

Small Molecule Therapeutics MTI-101 ( Cyclized HYD 1 ) Binds a CD 44 Containing Complex and Induces Necrotic Cell Death in Multiple Myeloma

L. Hazlehurst, R. Nair, J. Koomen, 2013 .

HYD1-induced increase in reactive oxygen species leads to autophagy and necrotic cell death in multiple myeloma cells

W. Dalton, A. Cress, L. Hazlehurst, 2009, Molecular Cancer Therapeutics.

HYD 1-induced increase in reactive oxygen species leads to autophagy and necrotic cell death in multiple myeloma cells

W. Dalton, A. Cress, L. Hazlehurst, 2009 .

Pitavastatin Is Anti-Leukemic in a Bone Marrow Microenvironment Model of B-Lineage Acute Lymphoblastic Leukemia

W. Geldenhuys, R. Nair, D. Piktel, 2022, Cancers.

Emerging strategies for targeting cell adhesion in multiple myeloma.

L. Hazlehurst, R. Nair, M. Emmons, 2012, Advances in pharmacology.

Bioactivity improvement via display of the hydrophobic core of HYD1 in a cyclic β‐hairpin‐like scaffold, MTI‐101

Daniel N. Santiago, W. Guida, P. Murray, 2020, Peptide science.

MTI-101 (Cyclized HYD1) Binds a CD44 Containing Complex and Induces Necrotic Cell Death in Multiple Myeloma

L. Hazlehurst, R. Nair, J. Koomen, 2013, Molecular Cancer Therapeutics.

Acquisition of Resistance toward HYD1 Correlates with a Reduction in Cleaved α4 Integrin Expression and a Compromised CAM-DR Phenotype

A. Cress, L. Hazlehurst, R. Nair, 2011, Molecular Cancer Therapeutics.

A Novel High-Throughput Screening System Identifies a Small Molecule Repressive for Matrix Metalloproteinase-9 Expression

Zhengxin Wang, R. Nair, D. Boyd, 2008, Molecular Pharmacology.

Enhancement of transgene expression by combining glucocorticoids and anti-mitotic agents during transient transfection using DNA-cationic liposomes.

J. Rodgers, R. Nair, L. Schwarz, 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

Emerging Opportunities for Targeting the Tumor–Stroma Interactions for Increasing the Efficacy of Chemotherapy

L. Hazlehurst, R. Nair, A. W. Gebhard, 2013 .

Targeting the dysfunctional mitochondrial respiration in drug resistant B-cell acute lymphoblastic leukemia

Quincy A. Hathaway, W. Geldenhuys, R. Nair, 2019, bioRxiv.

Chemotherapeutic Activity of Pitavastatin in Vincristine Resistant B-Cell Acute Lymphoblastic Leukemia

W. Geldenhuys, R. Nair, D. Piktel, 2023, Cancers.

Co-culture model of B-cell acute lymphoblastic leukemia recapitulates a transcription signature of chemotherapy-refractory minimal residual disease

W. Geldenhuys, R. Nair, K. Martin, 2021, Scientific Reports.

Pyrvinium Pamoate Use in a B cell Acute Lymphoblastic Leukemia Model of the Bone Tumor Microenvironment

Quincy A. Hathaway, W. Geldenhuys, R. Nair, 2020, Pharmaceutical Research.

Novel compounds that target lipoprotein lipase and mediate growth arrest in acute lymphoblastic leukemia.

W. Geldenhuys, R. Nair, D. Piktel, 2018, Bioorganic & medicinal chemistry letters.

Expression Cloning Identifies Transgelin (SM22) as a Novel Repressor of 92-kDa Type IV Collagenase (MMP-9) Expression*

R. Nair, D. Boyd, J. Solway, 2006, Journal of Biological Chemistry.

Role of STAT3 in Transformation and Drug Resistance in CML

L. Hazlehurst, R. Nair, Joel H. Tolentino, 2012, Front. Oncol..

A bisanthracycline (WP631) represses uPAR gene expression and cell migration of RKO colon cancer cells by interfering with transcription factor binding to a chromatin-accessible -148/-124 promoter region.

R. Nair, D. Boyd, W. Priebe, 2005, Oncology research.

Pyrvinium Pamoate Use in a B cell Acute Lymphoblastic Leukemia Model of the Bone Tumor Microenvironment

W. Geldenhuys, R. Nair, D. Piktel, 2020, Pharmaceutical Research.